PDS Biotechnology amended its $6,000,000 Promissory Note to require 100% of net proceeds from non-ATM equity financings to repay the holder. The change matters to investors because future Capital raises outside the ATM program will be directed to note redemption, while ATM proceeds remain subject to specified repayment terms.

Key Highlights

  • ATM proceeds exceeding 100% of the next installment and accrued interest will be split, with 40% retained by PDS Biotechnology and 60% paid to the holder.
  • The amended note requires weekly Remittance notices for qualifying ATM proceeds and payment of the applicable amount within one Business day.
  • The amendment becomes effective after execution, delivery and full payment of the installment due on September 14, 2026.

PDS Biotechnology Corp (NASDAQ: PDSB) amended its $6,000,000 promissory note with YA II PN, Ltd. on August 31, 2026, changing how proceeds from equity financings are applied. Net cash proceeds from equity or equity-linked financing outside the company’s ATM program must be directed entirely to Redemption of the note.

Equity Proceeds Redirected to Note Repayment

The note was originally issued on June 15, 2026, in the principal amount of $6,000,000. Under the revised ATM provisions, PDS Biotechnology must provide the holder with a weekly notice detailing net proceeds received during the prior week and pay the applicable amount within one business day. ATM proceeds are applied to the next installment’s principal and accrued interest. If those proceeds exceed 100% of the next installment and accrued interest, PDS Biotechnology may retain 40%, while 60% is paid to YA II PN and applied to later installments in reverse chronological order. The amendment also adds a provision covering non-ATM equity or equity-linked financings. Net cash proceeds from those transactions create a redemption amount equal to 100% of the proceeds, payable to the holder within five business days.

Effectiveness Depends on September Payment

The amended terms become effective once both parties have executed and delivered the agreement and PDS Biotechnology has paid the full installment due on September 14, 2026. The note’s Nasdaq listing-deficiency cure period is extended under the amendment. The agreement otherwise ratifies the existing note, which remains in force except for the specified changes. It also states that the holder has not waived any default, right or remedy under the note. The revised structure means non-ATM Equity Financing proceeds are contractually allocated to note redemption, while ATM proceeds follow the separate repayment and retention provisions.